Terns Pharmaceuticals, INC. (TERN) — 10-Q Filings

10-Q Filings (6)

• Terns Pharma Widens Q3 Loss Amid Rising R&D Spend — Nov 10, 2025 Risk: high
  Terns Pharmaceuticals, Inc. reported a net loss of $24.635 million for the three months ended September 30, 2025, an increase from a net loss of $21.945 million
• Terns Narrows Q2 Loss Amid R&D Cuts, Cash Runway to H2 2026 — Aug 5, 2025 Risk: high
  Terns Pharmaceuticals, Inc. reported no revenue for the three and six months ended June 30, 2025, consistent with its clinical-stage status. The company's net l
• Terns Pharmaceuticals Files Q1 2025 10-Q — May 8, 2025 Risk: medium
  Terns Pharmaceuticals, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information, including retained earnings and fair
• Terns Pharmaceuticals Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
  Terns Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 12, 2024, detailing its financial performance for the period ending September 30, 2024. Th
• Terns Pharmaceuticals Files Q2 2024 10-Q — Aug 5, 2024 Risk: medium
  Terns Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Terns Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — May 13, 2024 Risk: low
  Terns Pharmaceuticals, Inc. (TERN) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Terns Pharmaceuticals, Inc. filed a 10-Q report for the period

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX